查看文章

A ntipsychotic polypharmacy (APP), defined as the use of 2 or more antipsychotics, is common in schizophrenia, with a global median rate of 19.6%(interquartile range, 12.9%-35.0%), although substantial variations exist between treatment settings, regions, populations, and prescribers. 1 Reasons for APP are diverse and include trying to enhance antipsychotic efficacy or targeting different symptoms or symptom domains that are insufficiently addressed by antipsychotic monotherapy, including anxiety, insomnia, aggressive/impulsive behaviors, or negative symptoms. 2 APP has also been associated with the desire to lower the dose and/or reduce side effects of the original antipsychotic, the process of ongoing or aborted cross-titration, combination of different antipsychotic formulations, and prescriber and/or patient/family preference. 2 Interestingly, clinicians who prescribe more APP tend to be more experienced …